Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Futibatinib by Otsuka Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Futibatinib by Otsuka Pharmaceutical for Metastatic Breast Cancer: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Triple-Negative Breast Cancer (TNBC)....
(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Human Epidermal Growth Factor...
Futibatinib by Otsuka Pharmaceutical for Gastric Cancer: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia....
(Cedazuridine + decitabine) by Otsuka Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
(Cedazuridine + decitabine) is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia....
Futibatinib by Otsuka Pharmaceutical for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Futibatinib by Otsuka Pharmaceutical for Solid Tumor: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Futibatinib by Otsuka Pharmaceutical for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
Brexpiprazole by Otsuka Pharmaceutical for Post-Traumatic Stress Disorder (PTSD): Likelihood of Approval
Brexpiprazole is under clinical development by Otsuka Pharmaceutical and currently in Pre-Registration for Post-Traumatic Stress Disorder (PTSD). According to GlobalData,...
Futibatinib by Otsuka Pharmaceutical for Urethral Cancer: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Urethral Cancer. According to GlobalData, Phase...
Quabodepistat by Otsuka Pharmaceutical for Pulmonary Tuberculosis: Likelihood of Approval
Quabodepistat is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pulmonary Tuberculosis. According to GlobalData, Phase...
Futibatinib by Otsuka Pharmaceutical for Esophageal Cancer: Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
Futibatinib by Otsuka Pharmaceutical for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...
Pimitespib by Otsuka Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Delamanid by Otsuka Pharmaceutical for Pulmonary Tuberculosis: Likelihood of Approval
Delamanid is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Pulmonary Tuberculosis. According to GlobalData, Phase...
Futibatinib by Otsuka Pharmaceutical for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
OPC-415 by Otsuka Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval
OPC-415 is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
Centanafadine SR by Otsuka Pharmaceutical for Attention Deficit Hyperactivity Disorder (ADHD): Likelihood of Approval
Centanafadine SR is under clinical development by Otsuka Pharmaceutical and currently in Phase III for Attention Deficit Hyperactivity Disorder (ADHD)....